CHSY1 can activate succinate metabolism and PI3K-AKT pathway in CD8+T cells, and the combination of CHSY1 inhibitor and anti-PD1 therapy can reduce CRC liver metastases [56]. This evidence concerns the gene CD8A and colorectal carcinoma.